JAK/STAT signaling pathway molecules (STAT3, STAT5B, JAK1, and JAK3) have previously been shown to be recurrently mutated in various subtypes of PTCL [5, 7–9, 12]. This evidence concerns the gene JAK1 and mature T-cell and NK-cell non-Hodgkin lymphoma.